ENvue Medical, Inc. (FEED)
Nasdaq · Healthcare · Medical Devices
$0.26−25.71%as of Nov 5, 2026, 4:50 AM ET
- Market cap
- $240K
- 52-week range
- $0.121 – $73.08
- 52-week change
- −99.40%
- EPS (trailing)
- −$339.36
Fiscal year to Dec 2025
- Revenue
- $2.6M (−0.20%)
- Net income
- −$18.2M
- Operating margin
- −896.6%
- Diluted EPS
- −$26.69
- Free cash flow
- −$9.4M
From the company’s annual report on SEC EDGAR.
About ENvue Medical, Inc.
ENvue Medical, Inc., through its subsidiaries, focuses on non-invasive biological response-activating devices that target biofilm prevention, pain therapy, wound healing, and at home administration without medical professional assistance. Its product portfolio includes UroShield, an ultrasound-based product that is designed to prevent bacterial colonization and biofilm in urinary catheters, increase antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers UroShield Ultra, which is designed to prevent bacterial colonization and biofilm formation in urinary catheters; PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures. In addition, it provides PainShield MD, a single patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; PainShield Plus, a dual patch-based therapeutic ultrasound technology; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing.
Headquarters: Tyler, United States · 12 employees · envuemed.com